Stock Taper 
ACET
$9.06
▲ UP 0.55% (0.05)
KEY STATISTICS
Market Cap$84.70 M
52w High$17.44
52w Low$6.01
Dividend Yield0.14%
FrequencyQuarterly
P/E-0.79
Volume111.28K
Shares Out.9.35M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Chen Schor
COMPENSATION 2026
Salary$646,294
Stock Awards$0
Incentive Plan Pay$284,592
All Other Comp.$22,782
Total$1,465,747
ABOUT
SECTOR
Healthcare
WENT PUBLIC
January 26, 2018
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
102
PRICE TARGET
Target High$608.00
Target Low$18.00
Target Median$432.00
Target Consensus$352.67
UPCOMING EARNINGS
DateNov 11, 2026
DayWednesday
Rev. Est.—
NOV
11
WED
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 2025-12-30 | Reverse | 1:16 |
| 2020-09-16 | Reverse | 1:7 |
PRICE
$9.06 ▲ UP 0.55% (+$0.05)About Adicet Bio, Inc.
https://www.adicetbio.com ↗Adicet Bio, Inc. develops allogeneic gamma delta T cell therapies, including engineered CAR and TCR-like cells, for cancer treatment, with lead products ADI-001 in Phase I for non-Hodgkin's lymphoma and ADI-002 in preclinical for solid tumors.
INDUSTRY
Biotechnology
A PRODUCT ADICET BIO, INC. IS KNOWN FOR
Prulacabtagene leucel (prula-cel, formerly ADI-001)
Prulacabtagene leucel (prula-cel) is Adicet Bio's investigational allogeneic gamma delta CAR T cell therapy in Phase 1 trials for autoimmune diseases like lupus nephritis and systemic lupus erythematosus.
Revenue by Products
| Icon | PRODUCT | Q1-2018 | Q2-2018 | Q3-2018 | Q4-2018 |
|---|---|---|---|---|---|
 | Human Health | $91.93M | $374.51M ▲ | $80.85M ▼ | $84.98M ▲ |
 | Pharmaceutical Ingredients | $43.2M | $158.85M ▲ | $38.85M ▼ | $42.04M ▲ |
 | Performance Chemicals | $50.87M | $177.99M ▲ | $44.71M ▼ | $36.63M ▼ |
Revenue by Geography
| Map | REGION | Q2-2018 |
|---|---|---|
 | UNITED STATES | $535.7M |
 | GERMANY | $96.71M |
 | FRANCE | $36.64M |
 | Asia Pacific | $30.33M |
 | NETHERLANDS | $11.98M |
ETFS HOLDING THIS STOCK
ETFS HOLDING
15
LISTED HERE
4
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
100.00%
HOLDERS
83
TOP 12 OF 83 · RANKED BY POSITION SIZE
Orbimed Advisors LLC
Tang Capital Management LLC
Ra Capital Management, L.P.
Goldman Sachs Group Inc
Vanguard Group Inc
Carlyle Group Inc.
Aquilo Capital Management, LLC
Acadian Asset Management LLC
Abingworth Llp
Renaissance Technologies LLC
Blackrock Inc.
Regeneron Pharmaceuticals, Inc.
RATINGS SNAPSHOT
Overall rating: C+
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book4
Overall Score2
INSIDER TRADES
★
DIRECTOR, OFFICER: CHIEF MEDICAL OFFICER
Klickstein Lloyd
Purchase · 18.3K shares
2026-08-05
★
DIRECTOR
Chodakewitz Jeffrey
Purchase · 4.2K shares
2026-06-21
★
DIRECTOR
Peng Katie
Purchase · 4.2K shares
2026-06-21
★
DIRECTOR
Klickstein Lloyd
Purchase · 4.2K shares
2026-06-21
MOST RECENT ANALYST GRADES
GRADE SUMMARY
BUY 3
3 GRADES IN THE LAST 12 MONTHS
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 IMUX | $15.40 | COMPARE |
 ADAG | $3.68 | COMPARE |
 ACRV | $2.06 | COMPARE |
 GANX | $1.77 | COMPARE |
 NRXP | $3.55 | COMPARE |
 TCRX | $0.75 | COMPARE |
 HOWL | $0.94 | COMPARE |
 LITS | $0.98 | COMPARE |